Resellers’ Cancer Treatment Prices Draw Congressional Scrutiny
This article is for subscribers only.
The top Democrat on the U.S. House Oversight Committee has launched a probe into what he says are steep mark-ups of life-saving drugs by companies that buy them on a secondary market and resell them to hospitals.
The resellers targeted say they provide a valuable service and aren’t exploiting hospitals and pharmacies, and three of the five are pledging cooperation. Their prices for short-supply drugs average seven-fold typical prices, according to a survey by the Premier Healthcare Alliance.